World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
40184
World Ranking
10735
National Ranking
5519

Alexander Drilon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alexander Drilon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,267 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alexander Drilon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alexander Drilon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alexander Drilon is affiliated with Memorial Sloan Kettering Cancer Center in the United States and has contributed extensively to oncology and related biomedical fields. Their research encompasses both clinical and molecular aspects of cancer, with a particular focus on genetic mutations and targeted treatments.

The main fields of study in Drilon's work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

The subfields emphasize specialization areas such as:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Genetics

Drilon's research addresses multiple core topics, notably:

  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Immunotherapy and Biomarkers

Frequent co-authors in collaborative efforts include:

  • W. Marston Linehan
  • David S. Hong
  • Marc Ladanyi
  • Theodore W. Laetsch
  • Shivaani Kummar

Key publication venues where Drilon's work appears regularly are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Clinical Cancer Research

Representative recent scientific papers authored or co-authored by Drilon include:

  • "Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials" (2020, The Lancet Oncology)
  • "Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer" (2020, New England Journal of Medicine)
  • "Efficacy of Selpercatinib in RET -Altered Thyroid Cancers" (2020, New England Journal of Medicine)
  • "Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial" (2022, The Lancet Oncology)
  • "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration" (2020, Nature Medicine)

These publications highlight Drilon's involvement in trials and studies focusing on targeted therapies for cancers with specific genetic alterations, reflecting integration of clinical oncology and molecular biology.

Best Publications

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • NTRK fusion-positive cancers and TRK inhibitor therapy

    Emiliano Cocco;Maurizio Scaltriti;Alexander Drilon

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago

  • Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

    Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

    Lori J Wirth;Eric Sherman;Bruce Robinson;Benjamin Solomon

  • Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

    Paul K. Paik;Paul K. Paik;Alexander Drilon;Alexander Drilon;Pang Dian Fan;Helena Yu;Helena Yu

  • Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

    Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron

  • Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

    Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara

  • Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Alexander Drilon;Sai Hong Ignatius Ou;Byoung Chul Cho;Dong Wan Kim

  • NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

    James P. Solomon;Irina Linkov;Andrea Rosado;Kerry Mullaney

  • Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

    Bob T. Li;Ronglai Shen;Darren Buonocore;Zachary T. Olah

  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

    Alexander Drilon;Natasha Rekhtman;Maria Arcila;Lu Wang

  • Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

    Natasha Rekhtman;Maria C. Pietanza;Matthew D. Hellmann;Jarushka Naidoo

  • Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

    Jaclyn F. Hechtman;Ryma Benayed;David M. Hyman;Alexander Drilon

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

Frequent Co-Authors

David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Natasha Rekhtman
Natasha Rekhtman Memorial Sloan Kettering Cancer Center
Robert C. Doebele
Robert C. Doebele University of Colorado Denver
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternatives to a traditional MD degree, there are many online programs that can prepare you for rewarding careers in healthcare. For example, nursing is a popular pathway with a range of entry points. Some prospective students look for the easiest bsn program to get into to streamline their application process and start their nursing career sooner.

Those looking to avoid standardized admissions tests might also be interested in a nursing school that does not require teas test. This can make nursing more accessible for dedicated students who may struggle with high-stakes exams.

Not everyone in healthcare works directly with patients. Administrative and specialist roles are also in demand. You can pursue healthcare management through the best online healthcare administration degree programs. For those drawn to medical records or insurance, generous financial aid for medical billing and coding is available at many accredited schools.

By considering these diverse pathways, you can find flexible, reputable online education options that match your healthcare career ambitions.

Best Scientists Citing Alexander Drilon

Trending Scientists

Recently Published Articles